Chimerix Inc (CMRX)
0.8825
-0.01
(-0.95%)
USD |
NASDAQ |
Apr 26, 15:33
Chimerix Cash from Investing (TTM): 70.60M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 70.60M |
September 30, 2023 | -185.87M |
June 30, 2023 | 40.53M |
March 31, 2023 | 28.70M |
December 31, 2022 | 70.04M |
September 30, 2022 | 321.63M |
June 30, 2022 | 98.82M |
March 31, 2022 | 98.09M |
December 31, 2021 | -44.09M |
September 30, 2021 | -49.73M |
June 30, 2021 | -72.52M |
March 31, 2021 | -42.25M |
December 31, 2020 | 64.71M |
September 30, 2020 | 48.18M |
June 30, 2020 | 95.21M |
March 31, 2020 | 74.70M |
December 31, 2019 | 10.63M |
September 30, 2019 | 75.66M |
June 30, 2019 | 33.75M |
March 31, 2019 | 37.33M |
December 31, 2018 | 105.10M |
September 30, 2018 | 51.60M |
June 30, 2018 | 59.13M |
Date | Value |
---|---|
March 31, 2018 | 54.74M |
December 31, 2017 | 16.43M |
September 30, 2017 | 15.66M |
June 30, 2017 | 40.16M |
March 31, 2017 | 42.33M |
December 31, 2016 | 94.06M |
September 30, 2016 | 91.59M |
June 30, 2016 | 3.658M |
March 31, 2016 | -79.41M |
December 31, 2015 | -169.50M |
September 30, 2015 | -222.94M |
June 30, 2015 | -198.77M |
March 31, 2015 | -151.68M |
December 31, 2014 | -159.70M |
September 30, 2014 | -114.64M |
June 30, 2014 | -74.20M |
March 31, 2014 | -52.12M |
December 31, 2013 | 9.462M |
September 30, 2013 | -1.381M |
June 30, 2013 | -7.956M |
March 31, 2013 | -11.18M |
December 31, 2012 | -4.139M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-185.87M
Minimum
Sep 2023
321.63M
Maximum
Sep 2022
38.78M
Average
48.18M
Median
Sep 2020
Cash from Investing (TTM) Benchmarks
UFP Technologies Inc | -10.49M |
Dentsply Sirona Inc | -89.00M |
Arbutus Biopharma Corp | 50.77M |
Pacira BioSciences Inc | 77.54M |
Karyopharm Therapeutics Inc | 7.94M |